24/7 Wall Street
21 Nov 2026, 18:07 UTC · 1h ago
$500,000 in AbbVie and Gilead Could Pay More Than $11,000 a Year in Dividends
Impact · against what's priced in
The article provides no material catalysts for either company, as the highlighted dividend hikes and Medicare pricing risks are already integrated into current valuations. The only marginally new development is AbbVie's deal with Disco, though its impact on the overall revenue CAGR requirement is currently negligible.
- ABBV+0.10
Not in the price yet
- The price assumes
Late-stage oncology catalysts





